Prostate cancer is among the most common causes of death from cancer in men, and accounts for 10% of all new male cancers worldwide. The diagnosis and treatment of prostate cancer place a substantial physical and emotional burden on patients and their families, and have considerable financial implications for healthcare providers and society. Given that the risk of prostate cancer continues to increase with age, the burden of the disease is likely to increase in line with population life-expectancy. Reducing the risk of prostate cancer has gained increasing coverage in recent years, with proof of principle shown in the Prostate Cancer Prevention Trial with the type 2 5α-reductase (5AR) inhibitor, finasteride. The long latency period, high disease prevalence, and significant associated morbidity and mortality make prostate cancer a suitable target for a risk-reduction approach. Several agents are under investigation for reducing the risk of prostate cancer, including selenium/vitamin E and selective oestrogen receptors modulators (e.g. toremifene). In addition, the Reduction by Dutasteride of Prostate Cancer Events trial, involving >8000 men, is evaluating the effect of the dual 5AR inhibitor, dutasteride, on the risk of developing prostate cancer. A successful risk-reduction strategy might decrease the incidence of the disease, as well as the anxiety, cost and morbidity associated with its diagnosis and treatment.

5α-reductase inhibitors, Prevention, Prostate cancer, alpha tocopherol, androgen blood level, androgen deprivation therapy, androstanolone, brachytherapy, cancer diagnosis, cancer epidemiology, cancer incidence, cancer mortality, cancer prevention, cancer radiotherapy, cancer risk, cancer screening, cancer survival, clinical trial, cost of illness, disease course, disease marker, dutasteride, emotion, erectile dysfunction, fatigue, finasteride, functional assessment, gynecomastia, health care cost, human, isoflavone derivative, libido disorder, life expectancy, morbidity, muscle atrophy, osteoporosis, outcome assessment, patient satisfaction, placebo, priority journal, prostate cancer, prostate specific antigen, prostatectomy, psychological aspect, quality of life, risk reduction, selenium, short survey, sleep disorder, steroid 5alpha reductase inhibitor, toremifene, treatment outcome, urine incontinence, vitamin D, vitamin supplementation, weight gain
dx.doi.org/10.1111/j.1464-410X.2008.08206.x, hdl.handle.net/1765/18154
BJU International
Erasmus MC: University Medical Center Rotterdam

Fitzpatrick, J.M, Schulman, C, Zlotta, A.R, & Schröder, F.H. (2009). Prostate cancer: A serious disease suitable for prevention. BJU International, 103(7), 864–870. doi:10.1111/j.1464-410X.2008.08206.x